VIDEO: New targeted therapies for AML now available in practice

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

In 2023, we've had, actually, some recent approvals of even more targeted and non-targeted therapies for acute myeloid leukemia. For example, we've recently seen two new targeted agents for acute myeloid leukemia enter the commercial practice.

One is quizartinib [Vanflyta, Daiichi Sankyo], which is a second-generation FLT3 inhibitor, which was approved over the summer to be added to intensive chemotherapy for newly diagnosed, fit patients receiving 7+3 who have FLT3-ITD mutations. The data suggests that patients with FLT3-ITD, newly diagnosed mutant AML, can benefit from crizotinib [Xalkori, Pfizer] and replacing midostaurin [Rydapt, Novartis], which has been the FLT3 inhibitor for those individuals since 2017.

We've also seen a new IDH1 inhibitor, olutasidenib [Rezlidhia, Rigel Pharmaceuticals], which has been approved for patients with relapsed and refractory IDH1-mutant AML. And that drug is not necessarily replacing but an alternative regimen for treatment of those patients in addition to the current IDH1 inhibitor, ivosidenib [Tibsovo, Servier].

And lastly, we've seen, again, more development of oral chemotherapy, oral specifically hypomethylating agents for treatments of our patients with MDS and AML. We know that there's an oral decitabine/cedazuridine compound, Inqovi [Astex Pharmaceuticals], which is approved for high-risk MDS in place of IV decitabine. And we know that there's oral decitabine that was approved a couple years ago for patients with acute myeloid leukemia in remission who are not going on to additional transplant or consolidation. Whether those oral chemotherapy agents can make their way into more standard of care practice for AML patients really awaits the results of newer clinical trials.